Microbot Medical Inc. (MBOT), a preclinical medical device company, specializes in the design, development, and commercialization of transformational micro-robotic medical technologies. The company’s objective is to leverage its proprietary micro-robotic technologies to improve and reduce the complexity of clinical procedures.
Established in 2010 and headquartered in Hingham, Massachusetts, Microbot Medical Inc. is publicly traded on NASDAQ under the ticker symbol "MBOT". The company's innovative approach is fueled by two technology platforms – ViRob and TipCAT. The ViRob platform focuses on a miniature scale robotic technology, which can potentially navigate and penetrate tissues within the human body. The TipCAT platform, on the other hand, is a self-propelled, flexible, and semi-disposable endoscope that provides see & treat capabilities in anatomic sites that were previously inaccessible.
The company’s product line advances the field of minimally invasive surgery by providing a faster, cheaper, and less risky method due to its micro-robotic technologies. The devices it is developing, such as the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and Normal Pressure Hydrocephalus (NPH) and the Early Sepsis Detection System, hold the potential to revolutionize specific areas of medicine.
In terms of research and development, Microbot Medical Inc. consistently invests time and resources to continue the development and commercialization of its innovative products. For instance, the company's collaboration with Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, entails the development of a robotic endoluminal platform.
However, as a preclinical company, Microbot Medical Inc. faces some challenges. Its products are still in the development stage and have not yet received regulatory approval to proceed with human trials. The company is reliant on securing the necessary funding to continue its operations and move its product candidates through the clinical development process. Despite these challenges, Microbot Medical Inc.’s commitment to transform medical treatment with innovations in the field of micro-robotics makes it a pioneering entity in the medical device industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
HC Wainwright has revised its Q3 and full-year 2026 earnings estimates for Microbot Medical (NASDAQ:MBOT), lowering the Q3 EPS estimate to a loss of $0.08 per share from $0.06, while maintaining a "Buy" rating. The full-year 2026 estimate is now a loss of $0.29 per share. Despite mixed analyst sentiment, Microbot Medical recently reported a quarterly loss of $0.08 per share, in line with consensus, and revenue of $0.24 million, surpassing expectations.
B. Riley Financial has reaffirmed its "Buy" rating for Microbot Medical (NASDAQ:MBOT) but reduced its price target from $5.00 to $4.00, still implying a significant upside of 146%. Despite a positive overall "Moderate Buy" consensus from analysts, the stock is currently near its one-year low. Microbot Medical met EPS estimates and exceeded revenue expectations in its latest quarterly report, with institutional investors holding 16.3% of the company.
Microbot Medical (NASDAQ:MBOT) announced its earnings results, reporting a quarterly loss of $0.08 per share, which met analyst expectations, but revenue of $0.24 million fell short of the $0.33 million consensus. Following the announcement, shares declined 13.4% to $1.68, nearing the company's one-year low. Despite the revenue miss, analyst sentiment remains generally positive with a "Buy" rating and an average price target of $6.62.
Microbot Medical has partnered with Lovell Government Services to expand its reach into federal healthcare systems, gaining access to over 2,000 facilities for its LIBERTY endovascular robotic system. Concurrently, Microbot signed an agreement with Sanmina to establish a second manufacturing site, anticipating increased demand. This move aims to significantly grow its U.S. customer base and manufacturing capacity.
Microbot Medical Inc. (MBOT) reported a Q2 loss of $0.08 per share, in line with the Zacks Consensus Estimate, but missed revenue expectations with $0.24 million against an anticipated $0.31 million. Despite underperforming the market year-to-date, the company holds a Zacks Rank #2 (Buy), suggesting potential future outperformance based on favorable earnings estimate revisions. The Medical - Instruments industry, to which Microbot Medical belongs, is also performing well, ranking in the top 44% of Zacks industries.